This page shows what was measured, who it was measured in, and what that does not settle.
What Rifaximin does in the body
Travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli
4 )].
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · L36O5T016N · read 2026-08-29
Its recorded molecular formula is C43H51N3O11, weighing 785.9.
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 24 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Repeat Treatment Responders
✗ The study did not show it
Who was studied
NCT01543178
How many people
2583
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population
✗ The study did not show it
Who was studied
NCT02498418
How many people
739
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
The primary endpoint in this study is the assessment of safety and tolerability of rifaximin 600 mg QD compared to placebo.
✗ The study did not show it
Who was studied
NCT00328380
How many people
660
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
✗ The study did not show it
Who was studied
NCT00724126
How many people
637
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).
✗ The study did not show it
Who was studied
NCT00731679
How many people
623
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Incisional surgical site infection (SSI) rate
✗ The study did not show it
Who was studied
NCT04592289
How many people
622
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of XIFAXAN has not been established in pediatric patients less than 12 years of age with TD or in patients less than 18 years of age for HE and IBS-D.”
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-30
On older people, the label states: “Clinical studies with XIFAXAN for TD did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger subjects.”
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary There are no available data on XIFAXAN use in pregnant women to inform any drug-associated risks.”
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of rifaximin in human milk, the effects of rifaximin on the breastfed infant, or the effects of rifaximin on milk production.”
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-30
On people with reduced liver function, the label states: “Following administration of XIFAXAN 550 mg twice daily to patients with a history of hepatic encephalopathy, the systemic exposure (i.e., AUCτ) of rifaximin was about 10-, 14-, and 21-fold higher in those patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) and severe (Child-Pugh Class C) hepatic impairment, respectively, compared to that in healthy volunteers.”
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-30
On people with reduced kidney function, the label states: “The pharmacokinetics of rifaximin in patients with impaired renal function has not been studied.”
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as tablet, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
24 products list this as an active ingredient in the United States drug directory. 24 of them contain it and nothing else.
FDA National Drug Code directory · 38779-3387 · read 2026-08-29
They are sold as powder, tablet and tablet, coated, taken oral.
FDA National Drug Code directory · 38779-3387 · read 2026-08-29
The regulator's established pharmacologic class for it is rifamycin antibacterial [epc] and rifamycins [cs].
FDA National Drug Code directory · 38779-3387 · read 2026-08-29
3 published labels name it as an active ingredient. 3 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-29
XIFAXAN is oral at 3 DOSAGE FORMS AND STRENGTHS XIFAXAN is a pink-colored biconvex tablet and is available in the following strengths: • 200 mg – a round tablet debossed with “Sx” on one side and plain on the other. • 550 mg – an oval tab…, recorded as fda label in effect 2025-06-25 in the United States.
US prescribing information · c5e8e2fd-7087-4b78-9181-cc259c0be2f1 · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Rifaximin studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Rifaximin are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
3 documents were read for this substance.
RNAWiki source record
3 of them state the same halfLife, and they agree.
RNAWiki source record
3 of them state the same tMax, and they agree.
RNAWiki source record
3 of them state the same proteinBinding, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
L36O5T016N
RxNorm concept
429662
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
10 approved applications cover products containing this substance. The earliest was NDA021361, approved 20040525 to SALIX PHARMS.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (11)
Q1
On the Rifaximin label: indicated for what?
"To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and…": indications and usage on Rifaximin's label. DailyMed label · 7afafa63-3236-4212-9589-045db6b01c0b · 2025-08-27
Q2
158 registered trials of Rifaximin — at which phases?
Registered studies posting no result
120 of 158
158 registered studies of Rifaximin: 44 phase2, 39 phase3, 37 phase4, 34 na, 12 phase1, 6 early phase1, 3 na or unstated. CLINICALTRIALS_SNAPSHOT · 2026-09-01
231 with a PubMed record
Show the evidence
phase2
44
phase3
39
phase4
37
na
34
phase1
12
early phase1
6
8 more recorded rows
na or unstated
3
completed
71
unknown
33
terminated
19
recruiting
17
withdrawn
11
not yet recruiting
6
suspended
1
recorded 2026-09-01 · last checked 2026-09-04
Q3
27 of Rifaximin's trials stopped: futility/efficacy, accrual/recruitment, funding/business, other?
futility/efficacy (1), accrual/recruitment (11), funding/business (1) and other (14): Rifaximin's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Difficult to recruit participants"; 27 of 158 registered studies
Show the evidence
Trial
NCT00364689
terminated; "Difficult to recruit participants"
NCT00577772
terminated; "Enrollment Goal Not Met"
NCT00875875
withdrawn; "No study population in Mexico (H1N1). Study withdrawn from IRB consideration."
NCT01355575
terminated; "Primary endpoint data review concluded no further patients required."
NCT01842113
terminated; "PI Initiated study - PI left facility"
NCT01846663
terminated; "Study was determined to be infeasible."
14 further recorded trials
NCT01846806
terminated; "PI no longer at NYUMC"
NCT01951209
terminated; "Inadequate enrollment prior to expiration date of unreplaceable blinded investigational product"
NCT02011841
withdrawn; "We failed to recruit patients"
NCT02439307
terminated; "The study was terminated because of the reconversion of the hospital to care for patients with COVID19. For this reason, it was not possible to continue recruiting and monitoring patients for this clinical study."
NCT02555293
terminated; "Prematurely terminated due to organisational reasons"
NCT02620007
terminated; "insufficient recruitment"
NCT02738905
withdrawn; "insufficient support"
NCT02836353
terminated; "Reached scientific goals, further recruitment would not further advance the findings of study."
NCT02920242
terminated; "Terminated due to low enrollment"
NCT03115697
withdrawn; "lack of funds"
NCT03462966
terminated; "recruitment challenges"
NCT03575195
suspended; "Conducting an interim analysis"
NCT03818672
terminated; "Study determined to be infeasible."
NCT04154735
withdrawn; "Discontinued by Investigator"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Rifaximin used Rifaximin 400 mg orally three times a day for 10 days total — over how long?
Human studies of Rifaximin used "Rifaximin 400 mg orally three times a day for 10 days total". ClinicalTrials.gov · 2026-09-01
18 recorded entries; human; orally, tablet; also "Rifaximin SSD 40 mg IR tablet", "Rifaximin SSD 80 mg IR tablet", "Rifaximin SSD 40 mg SER tablet"
Show the evidence
human
NCT01137955
orally; Rifaximin 400 mg orally three times a day for 10 days total
NCT01904409
tablet; Rifaximin SSD 40 mg IR tablet
NCT01904409
tablet; Rifaximin SSD 80 mg IR tablet
NCT01904409
tablet; Rifaximin SSD 40 mg SER tablet
NCT01904409
tablet; Rifaximin SSD 80 mg SER tablet
NCT02488993
Prospective Phase Rifaximin-α 550mg
12 more recorded rows
humanNCT02488993
Prospective Phase No Rifaximin-α 550mg
humanNCT03150459
Rifaximin 400 mg
humanNCT03219528
Rifaximin 550 MG
humanNCT03758144
Rifaximin 200 MG
humanNCT04043897
Rifaximin 550mg
humanNCT05408910
Rifaximin 550 MG Oral Tablet [XIFAXAN]
humanNCT05786859
Rifaximin 200 mg
humanNCT06223685
Rifaximin (Xifaxan) 1200mg/day
humanNCT06223685
XIFAXAN® (Rifaximin) 1600mg/day
humanNCT06538077
Placebo for Rifaximin 550mg
humanNCT06852274
Rifaximin 400 mg Oral Tablet
humanNCT07285785
Rifaximin 200 mg Tablet
recorded 2026-09-01 · last checked 2026-09-04
Q5
Rifaximin's half-life is 30 minutes — which schedules were studied?
30 minutes, the half-life Rifaximin's label states: "Mean (± SD) Pharmacokinetic Parameters of Rifaximin Following XIFAXAN 550 mg Three Times a Day in IBS-D Patients and Healthy Subjects Healthy Subjects IBS-D Patients Single- Dose (Day 1) n=12 Multiple- Dose (Day 14) n=14 Single- Dose (Day 1) n=24 Multiple- Dose (Day 14) n=24 C max (ng/mL) 4.04 (1.51) 2.39 (1.28) 3.49…" DailyMed label · 7afafa63-3236-4212-9589-045db6b01c0b · 2025-08-27
tmax 14 days.
Show the evidence
half lifepharmacokinetics
30 minutes; Mean (± SD) Pharmacokinetic Parameters of Rifaximin Following XIFAXAN 550 mg Three Times a Day in IBS-D Patients and Healthy Subjects Healthy Subjects IBS-D Patients Single- Dose (Day 1) n=12 Multiple- Dose (Day 14) n=14 Single- Dose (Day 1) n=24 Multiple- Dose (Day 14) n=24 C max (ng/mL) 4.04 (1.51) 2.39 (1.28) 3.49 (1.36) 4.22 (2.66) T max (h)ª 0.75 (0.5-2.1) 1.00 (0.5-2.0) 0.78 (0-2) 1.00…
tmaxpharmacokinetics
14 days; Irritable Bowel Syndrome with Diarrhea In patients with irritable bowel syndrome with diarrhea (IBS-D) treated with XIFAXAN 550 mg three times a day for 14 days, the median Tmax was 1 hour and mean Cmax and AUC were generally comparable with those in healthy subjects.
metabolismpharmacokinetics
Metabolism In an in vitro study, rifaximin was metabolized mainly by CYP3A4.
recorded 2025-08-27 · last checked 2026-09-04
Q6
Which running trial of Rifaximin could settle lifespan?
NCT05502913 measures Progression-free Survival (PFS), reading out 2028-06-30.
1 open trial; n 80; "Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer"
Show the evidence
TrialNCT05502913
"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer"; n 80; "Progression-free Survival (PFS)"; 2028-06-30
Q7
Which 37 trials of Rifaximin posted no result?
Posted no result
37 of 37 completed trials
Registrations
NCT00098384, NCT00259155, NCT00269412, NCT00328380, NCT00743912 and NCT00355602, and 31 more
Completion dates
oldest 2003-09; newest 2023-06-10
Show the evidence
Trial
NCT00098384
2003-09
NCT00259155
2007-01
NCT00269412
2008-09
NCT00328380
2008-09
NCT00743912
2008-11
NCT00355602
2008-12
14 further recorded trials
NCT00967096
2009-04
NCT02068482
2012-08
NCT00979056
2012-10
NCT01069133
2012-12
NCT02009618
2013-10
NCT02009592
2014-02
NCT01695174
2014-03
NCT01946906
2014-12
NCT01643083
2015-05
NCT01904409
2015-07
NCT01769040
2016-01
NCT02158182
2016-06
NCT01670149
2016-07
NCT02019784
2016-10
Q8
At the median, Rifaximin's trials enrolled 60 people — anything larger?
Median enrolment
60
Largest enrolment
2583
Registered trials counted
158
Q9
What do 812 spontaneous reports say about Rifaximin — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Rifaximin appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 812 reaction mentions were counted: hospitalisation 182; diarrhoea 125; hepatic encephalopathy 82; inability to afford medication 81. FAERS via Open Targets · CHEMBL1617 · 2026-06-24
Show the evidence
hospitalisation
182
diarrhoea
125
hepatic encephalopathy
82
inability to afford medication
81
confusional state
66
condition aggravated
59
4 more recorded rows
abdominal pain
57
ammonia increased
57
therapy interrupted
57
hepatic cirrhosis
46
recorded 2026-06-24 · last checked 2026-09-04
Q10
Which 10 reactions does Rifaximin's label not list?
( 7.2 ) 7.1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin.
drug_interactions
In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
drug_interactions
Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed [see Warnings and Precautions ( 5.5 ), Clinical Pharmacology ( 12.3 )].
drug_interactions
7.3 CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] .
drug_interactions
However, in patients with normal liver function, XIFAXAN at the recommended dosing regimen is not expected to induce CYP3A4.
drug_interactions
It is unknown whether rifaximin can have a significant effect on the pharmacokinetics of concomitant CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations.
2 more recorded rows
Interaction statementpharmacokinetics
Metabolism In an in vitro study, rifaximin was metabolized mainly by CYP3A4.
Interaction statementpharmacokinetics
Drug Interaction Studies An in vitro study suggests that rifaximin is a substrate of CYP3A4.
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.